Anees B Chagpar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1264660/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Does Localization Technique Matter for Non-palpable Breast Cancers?. American Surgeon, 2022, 88, 2871-2876.	0.4	5
2	Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care in Cancer, 2022, 30, 2027-2036.	1.0	14
3	Factors Affecting Time to Surgery in Breast Cancer Patients. American Surgeon, 2022, 88, 648-652.	0.4	3
4	Sociodemographic factors affecting telemedicine access: AÂpopulation-based analysis. Surgery, 2022, 171, 793-798.	1.0	6
5	Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis. Breast Cancer Research and Treatment, 2022, 192, 369-373.	1.1	4
6	The effect of emotional disorders on adherence to mammography screening guidelines. Breast Cancer Research and Treatment, 2022, 192, 623.	1.1	0
7	Integrating Palliative Care Into Self-management of Breast Cancer. Cancer Nursing, 2022, Publish Ahead of Print, .	0.7	0
8	Concordance in Breast Cancer Grading by Artificial Intelligence on Whole Slide Images Compares With a Multi-Institutional Cohort of Breast Pathologists. Archives of Pathology and Laboratory Medicine, 2022, 146, 1369-1377.	1.2	12
9	Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Npj Breast Cancer, 2022, 8, 29.	2.3	4
10	Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence–Guided System. JAMA Surgery, 2022, 157, 573.	2.2	10
11	Disparities in Breast Cancer Screening Between Caucasian and Asian American Women. Journal of Surgical Research, 2022, 277, 110-115.	0.8	8
12	Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC Journal of Clinical Oncology, 2022, 40, 516-516.	0.8	0
13	Omission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care. Journal of Surgical Research, 2022, 279, 393-397.	0.8	1
14	Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy. Modern Pathology, 2021, 34, 701-709.	2.9	23
15	Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma In Situ. Journal of the American College of Surgeons, 2021, 232, 373-378.	0.2	15
16	Do Obese Patients Present With More Advanced Breast Cancer?. American Surgeon, 2021, 87, 56-60.	0.4	2
17	Resection of Cavity Shave Margins in Stage 0–III Breast Cancer Patients Undergoing Breast Conserving Surgery. Annals of Surgery, 2021, 273, 876-881.	2.1	39

18 Milestone Studies in Breast Cancer Surgery. , 2021, , 9-17.

#	Article	IF	CITATIONS
19	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer, 2021, 7, 9.	2.3	35
20	Factors Associated With a Delay in Postmastectomy Radiation Therapy. American Surgeon, 2021, 87, 000313482096628.	0.4	0
21	Enhanced Recovery After Surgery: Moving Toward Best Practice. Annals of Surgical Oncology, 2021, 28, 856-857.	0.7	3
22	Guide to Enhanced Recovery for Cancer Patients Undergoing Breast Surgery and Reconstruction. Annals of Surgical Oncology, 2021, 28, 6943-6946.	0.7	2
23	Debate: Postmastectomy Radiation Therapy in T1/2N1 Disease. Annals of Surgical Oncology, 2021, 28, 5456-5460.	0.7	4
24	Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast-Conservation Surgery. Annals of Surgical Oncology, 2021, 28, 5663-5667.	0.7	3
25	ASO Visual Abstract: AssessingÂInterobserver Variability ofÂCosmetic OutcomeÂAssessmentÂin Breast Cancer Patients Undergoing Breast Conservation Surgery. Annals of Surgical Oncology, 2021, 28, 632.	0.7	3
26	ASO Visual Abstract: Debate: Postmastectomy Radiation Therapy in T1/2N1 Disease. Annals of Surgical Oncology, 2021, 28, 648.	0.7	1
27	Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2021, 28, 5610-5616.	0.7	16
28	ASO Author Reflections: "Right-Sizing―Radiation Therapy After Mastectomy. Annals of Surgical Oncology, 2021, , 1.	0.7	0
29	ASO Author Reflections: Shouldn't Beauty be in the Eye of the Beholder?. Annals of Surgical Oncology, 2021, , 1.	0.7	0
30	Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. Contemporary Clinical Trials, 2021, 109, 106508.	0.8	8
31	Do Obese Breast Cancer Patients Have More Complications and a Longer Length of Stay After Mastectomy Than Nonobese Patients?. American Surgeon, 2021, 87, 1099-1106.	0.4	6
32	Factors Affecting Total Operating Time in Patients Undergoing Mastectomy With and Without Reconstruction. American Surgeon, 2021, 87, 1107-1111.	0.4	2
33	Are we choosing wisely? Drivers of preoperative MRI use in breast cancer patients. American Journal of Surgery, 2021, , .	0.9	6
34	Factors Affecting Telehealth Availability Among Breast Centers During the Pandemic. Journal of the American College of Surgeons, 2021, 233, S35.	0.2	0
35	ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density. Journal of the American College of Radiology, 2021, 18, S456-S473.	0.9	36
36	Is nipple sparing mastectomy associated with increased complications, readmission and length of stay compared toÂskinÂsparing mastectomy?. American Journal of Surgery, 2020, 219, 1030-1035.	0.9	9

#	Article	IF	CITATIONS
37	Effect of decision-making resources on satisfaction with decision to undergo contralateral prophylactic mastectomy (CPM). American Journal of Surgery, 2020, 219, 1036-1038.	0.9	2
38	Factors Associated with Reconstruction in Patients Undergoing Mastectomy. American Surgeon, 2020, 86, 134-139.	0.4	2
39	ls There a Bias Against Obese Patients in the Treatment of Breast Cancer?. American Surgeon, 2020, , 000313482098487.	0.4	0
40	Factors Associated with Reconstruction in Patients Undergoing Mastectomy. American Surgeon, 2020, 86, 134-139.	0.4	1
41	Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. Practical Radiation Oncology, 2019, 9, e257-e265.	1.1	2
42	Active Participation in Decision-Making in Contralateral Prophylactic Mastectomy for Patients With Breast Cancer. Journal of Surgical Research, 2019, 242, 129-135.	0.8	3
43	Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clinical Cancer Research, 2019, 25, 5398-5406.	3.2	58
44	The impact of communication style on patient satisfaction. Breast Cancer Research and Treatment, 2019, 176, 349-356.	1.1	16
45	Defining Why the Re-excision Rate Dropped. Annals of Surgical Oncology, 2019, 26, 1176-1177.	0.7	6
46	Clinicopathological Features of Young Versus Older Patients With Breast Cancer at a Single Pakistani Institution and a Comparison With a National US Database. Journal of Global Oncology, 2019, 5, 1-6.	0.5	21
47	Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy. American Surgeon, 2019, 85, 768-771.	0.4	4
48	Factors associated with decision to undergo contralateral prophylactic mastectomy versus unilateral mastectomy. American Journal of Surgery, 2019, 218, 170-174.	0.9	11
49	Reply: Complications in unilateral breast cancer patients who undergo contralateral prophylactic mastectomy versus unilateral mastectomy. Surgery, 2019, 165, 486-496.	1.0	0
50	Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy. American Surgeon, 2019, 85, 768-771.	0.4	2
51	Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer. Breast Cancer Research and Treatment, 2018, 169, 333-340.	1.1	16
52	Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected?. Journal of the American College of Surgeons, 2018, 227, 13-21.	0.2	4
53	Distress and quality of life in an ethnically diverse sample awaiting breast cancer surgery. Journal of Health Psychology, 2018, 23, 1438-1451.	1.3	9
54	On baseball and breast cancer. American Journal of Surgery, 2018, 215, 353-356.	0.9	0

#	Article	IF	CITATIONS
55	Margins and Breast Cancer. , 2018, , 59-69.		Ο
56	Does the Day of the Week a Mastectomy is Performed Influence Length of Stay?. American Surgeon, 2018, 84, 228-230.	0.4	0
57	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. Cell Reports, 2018, 25, 1446-1457.	2.9	76
58	Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. Breast Journal, 2018, 24, 976-980.	0.4	14
59	Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clinical Epigenetics, 2018, 10, 112.	1.8	40
60	Should Reexcision Rates in Breast Cancer Care be a Quality Measure?. Annals of Surgical Oncology, 2018, 25, 2818-2822.	0.7	4
61	Quality of Life and Body Image as a Function of Time from Mastectomy. Annals of Surgical Oncology, 2018, 25, 3044-3051.	0.7	13
62	Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Research and Treatment, 2018, 172, 105-112.	1.1	24
63	Complications in patients with unilateral breast cancer who undergo contralateral prophylactic mastectomy versus unilateral mastectomy. Surgery, 2018, 164, 1347-1350.	1.0	14
64	Impact of anticipated financial burden on patient decision to undergo contralateral prophylactic mastectomy. Surgery, 2018, 164, 856-865.	1.0	6
65	Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. American Surgeon, 2018, 84, 1-6.	0.4	11
66	How I treat breast cancer with positive lymph nodes. Clinical Advances in Hematology and Oncology, 2018, 16, 486-490.	0.3	0
67	Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals of Surgery, 2017, 265, 39-44.	2.1	21
68	Sentinel lymph node biopsy in low risk settings. American Journal of Surgery, 2017, 214, 489-494.	0.9	3
69	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Annals of Surgical Oncology, 2017, 24, 375-397.	0.7	61
70	Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?. American Journal of Surgery, 2017, 214, 1082-1088.	0.9	29
71	Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?― American Journal of Surgery, 2017, 214, 1089-1090.	0.9	0
72	Regional variation in breast cancer surgery: Results from the National Cancer Database (NCDB). American Journal of Surgery, 2017, 214, 907-913.	0.9	20

#	Article	IF	CITATIONS
73	Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals of Surgical Oncology, 2017, 24, 3073-3081.	0.7	32
74	Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer. Clinical Cancer Research, 2017, 23, 1193-1199.	3.2	26
75	Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2017, 24, 660-668.	0.7	21
76	Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011. American Journal of Surgery, 2017, 213, 426-432.	0.9	13
77	Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients?. American Surgeon, 2017, 83, 704-708.	0.4	2
78	American Society of Clinical Oncology Multidisciplinary Cancer Management Course: Connecting Lives, Cancer Care, Education, and Compassion in Zimbabwe—A Pilot for Efforts of Sustainable Benefit?. Journal of Global Oncology, 2017, 3, 409-417.	0.5	6
79	Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. Journal of Oncology Practice, 2017, 13, e1012-e1020.	2.5	6
80	Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients?. American Surgeon, 2017, 83, 704-708.	0.4	1
81	Variation in Follow-up of Asymptomatic Breast Cancer Patients: Can We Choose More Wisely?. American Surgeon, 2016, 82, 188-190.	0.4	0
82	Factors Associated with Persistently Positive Margin Status after Breast-Conserving Surgery in Women with Breast Cancer: An Analysis of the National Cancer Database. American Surgeon, 2016, 82, 748-752.	0.4	4
83	Collective Wisdom: Lobular Carcinoma of the Breast. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 18-21.	1.8	27
84	Variation in Practice of the Diagnostic Workup of Asymptomatic Patients Diagnosed with Invasive Breast Cancer. Frontiers in Oncology, 2016, 6, 56.	1.3	1
85	Reply to smoking cessation for patients with cancer: "The Emperor's New Clothesâ€: Cancer, 2016, 122, 2926-2926.	2.0	0
86	Smoking, cessation, and cessation counseling in patients with cancer: A populationâ€based analysis. Cancer, 2016, 122, 1247-1253.	2.0	70
87	Features of triple-negative breast cancer. Medicine (United States), 2016, 95, e4614.	0.4	138
88	Moving Toward Improved Teamwork in Cancer Care: The Role of Psychological Safety in Team Communication. Journal of Oncology Practice, 2016, 12, 1000-1011.	2.5	33
89	Integrating palliative care into self-management of breast cancer: Protocol for a pilot randomized controlled trial. Contemporary Clinical Trials, 2016, 48, 133-138.	0.8	1
90	Racial Differences in Utilization of Breast Conservation Surgery: Results from the National Cancer Data Base (NCDB). Annals of Surgical Oncology, 2016, 23, 3272-3283.	0.7	15

#	Article	IF	CITATIONS
91	Surgical Margins and Minimizing the Need for Re-excision. Breast Diseases, 2016, 27, 186-188.	0.0	0
92	Contrary To Conventional Wisdom, Physicians Abandoned A Breast Cancer Treatment After A Trial Concluded It Was Ineffective. Health Affairs, 2016, 35, 1309-1315.	2.5	17
93	Troubleshooting Sentinel Lymph Node Biopsy in Breast Cancer Surgery. Annals of Surgical Oncology, 2016, 23, 3459-3466.	0.7	20
94	Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research, 2016, 18, 78.	2.2	75
95	Breast cancer biology varies by method of detection and may contribute to overdiagnosis. Surgery, 2016, 160, 454-462.	1.0	15
96	Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study. Journal of Clinical Oncology, 2016, 34, 669-676.	0.8	138
97	Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer. Clinical Breast Cancer, 2016, 16, 59-62.	1.1	14
98	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 26-33.	3.2	49
99	Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer Journal of Clinical Oncology, 2016, 34, 564-564.	0.8	2
100	Collective Wisdom: Lobular Carcinoma of the Breast. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 18-21.	1.8	15
101	Do non-melanoma skin cancer survivors use tanning beds less often than the general public?. Dermatology Online Journal, 2016, 22, .	0.2	1
102	Variation in Follow-up of Asymptomatic Breast Cancer Patients: Can We Choose More Wisely?. American Surgeon, 2016, 82, e188-90.	0.4	0
103	Factors Associated with Persistently Positive Margin Status after Breast-Conserving Surgery in Women with Breast Cancer: An Analysis of the National Cancer Database. American Surgeon, 2016, 82, 748-52.	0.4	2
104	Variation in metastatic workup for patients with invasive breast cancer. American Journal of Surgery, 2015, 210, 1147-1154.e2.	0.9	8
105	Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer, 2015, 121, 2544-2552.	2.0	162
106	A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal of Medicine, 2015, 373, 503-510.	13.9	282
107	Systematic Approach to Providing Breast Cancer Survivors With Survivorship Care Plans: A Feasibility Study. Journal of Oncology Practice, 2015, 11, e170-e176.	2.5	13
108	Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal of Clinical Oncology, 2015, 33, 4267-4276.	0.8	83

#	Article	IF	CITATIONS
109	Maintenance of Certification: What Everyone Needs to Know. Annals of Surgical Oncology, 2015, 22, 1051-1054.	0.7	2
110	Surgical Management of Hereditary Breast Cancer. Current Breast Cancer Reports, 2015, 7, 43-47.	0.5	0
111	Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain, Behavior, and Immunity, 2015, 48, 102-114.	2.0	56
112	Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database. Journal of the American College of Surgeons, 2015, 220, 1063-1069.	0.2	152
113	Characteristics of Multifocal and Multicentric Breast Cancers. Annals of Surgical Oncology, 2015, 22, 2475-2482.	0.7	32
114	Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs, 2015, 34, 592-600.	2.5	15
115	The Left Sided Predominance of Breast Cancer is Decreasing. Breast Journal, 2015, 21, 213-215.	0.4	3
116	Does three-dimensional intraoperative specimen imaging reduce the need for re-excision inÂbreast cancer patients? A prospective cohortÂstudy. American Journal of Surgery, 2015, 210, 886-890.	0.9	23
117	Cavity Shave Margins in Breast Cancer. New England Journal of Medicine, 2015, 373, 2186-2188.	13.9	10
118	Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors Journal of Clinical Oncology, 2015, 33, 1091-1091.	0.8	2
119	Epidemiology of Ductal Carcinoma In Situ. , 2015, , 1-11.		2
120	Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM) Journal of Clinical Oncology, 2015, 33, 1012-1012.	0.8	0
121	Predictors of recurrence in patients diagnosed with ductal carcinoma in situ. American Surgeon, 2015, 81, 48-51.	0.4	4
122	Response. Journal of the National Cancer Institute, 2014, 106, dju198-dju198.	3.0	0
123	A Prediction Model for the Presence of Axillary Lymph Node Involvement in Women with Invasive Breast Cancer: A Focus on Older Women. Breast Journal, 2014, 20, 147-153.	0.4	20
124	Impact of Financial Burden of Cancer on Survivors' Quality of Life. Journal of Oncology Practice, 2014, 10, 332-338.	2.5	341
125	Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal of the National Cancer Institute, 2014, 106, dju008.	3.0	33
126	Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal of the National Cancer Institute, 2014, 106, .	3.0	22

#	Article	IF	CITATIONS
127	Smoking and Breast Cancer Recurrence after Breast Conservation Therapy. International Journal of Breast Cancer, 2014, 2014, 1-5.	0.6	19
128	Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy. Surgical Oncology Clinics of North America, 2014, 23, 423-430.	0.6	10
129	The Number of Lymph Nodes Dissected in Breast Cancer Patients Influences the Accuracy of Prognosis. Annals of Surgical Oncology, 2014, 21, 389-394.	0.7	17
130	Promoting quality breast cancer care: Psychosocial distress screening. Palliative and Supportive Care, 2014, 12, 75-80.	0.6	7
131	Breast Cancer Laterality Does Not Influence Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality. International Journal of Radiation Oncology Biology Physics, 2014, 90, 329-334.	0.4	40
132	The axilla. , 2014, , 109-126.		1
133	Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?. Journal of Clinical Oncology, 2014, 32, 107-107.	0.8	0
134	Factors correlated with HPV vaccination in the LGBT community Journal of Clinical Oncology, 2014, 32, 202-202.	0.8	0
135	Worry about breast cancer recurrence: a population-based analysis. American Surgeon, 2014, 80, 640-5.	0.4	14
136	State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports, 2013, 5, 125-133.	0.5	0
137	Factors Associated with Breast MRI Use: A Population-Based Analysis. Annals of Surgical Oncology, 2013, 20, 1798-1805.	0.7	3
138	Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. American Journal of Surgery, 2013, 206, 478-481.	0.9	33
139	Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast. American Journal of Surgery, 2013, 206, 682-685.	0.9	10
140	Is There a Correlation Between Breast Cancer Molecular Subtype Using Receptors as Surrogates and Mammographic Appearance?. Annals of Surgical Oncology, 2013, 20, 3247-3253.	0.7	16
141	Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Research and Treatment, 2013, 141, 155-163.	1.1	52
142	Do healthcare professionals discuss the emotional impact of cancer with patients?. Psycho-Oncology, 2013, 22, 2046-2050.	1.0	17
143	The Cost of Breast Cancer Screening in the Medicare Population. JAMA Internal Medicine, 2013, 173, 220.	2.6	60
144	Does removal of DCIS decrease the incidence of invasive breast cancer?. Journal of Clinical Oncology, 2013, 31, 2-2.	0.8	0

#	Article	IF	CITATIONS
145	The impact of survivorship care plans on knowledge among breast cancer survivors Journal of Clinical Oncology, 2013, 31, 124-124.	0.8	Ο
146	Factors associated with unplanned breast cancer readmissions Journal of Clinical Oncology, 2013, 31, 131-131.	0.8	2
147	Does time to definitive treatment matter in patients with ductal carcinoma in situ?. American Surgeon, 2013, 79, 561-5.	0.4	9
148	How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees. International Journal of Radiation Oncology Biology Physics, 2012, 84, e131-e137.	0.4	7
149	Validation of the Louisville Breast Sentinel Node Prediction Models and a Proposed Modification to Guide Management of the Node Positive Axilla. American Surgeon, 2012, 78, 761-765.	0.4	5
150	Stress, Coping, and Circadian Disruption Among Women Awaiting Breast Cancer Surgery. Annals of Behavioral Medicine, 2012, 44, 10-20.	1.7	54
151	Validation of the Louisville breast sentinel node prediction models and a proposed modification to guide management of the node positive axilla. American Surgeon, 2012, 78, 761-5.	0.4	2
152	Innovation in surgery: from imagination to implementation. American Journal of Surgery, 2011, 202, 641-645.	0.9	4
153	<i>The Impact of Lymphovascular Invasion on Lymph Node Status in Patients with Breast Cancer</i> . American Surgeon, 2011, 77, 874-877.	0.4	19
154	Primary tumor size, not race, determines outcomes in women with hormone-responsive breast cancer. Surgery, 2011, 150, 796-801.	1.0	12
155	Lymph Node Ratio: A Proposed Refinement of Current Axillary Staging in Breast Cancer Patients. Journal of the American College of Surgeons, 2011, 213, 45-52.	0.2	50
156	Comparing Prediction Models: The Distinction Between Clinical and Statistical Significance. Annals of Surgical Oncology, 2011, 18, 265-265.	0.7	2
157	Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer. Annals of Surgical Oncology, 2011, 18, 3143-3148.	0.7	42
158	How Can the AJCC Staging System Be Improved?. Current Breast Cancer Reports, 2011, 3, 104-108.	0.5	0
159	Role of American Society of Clinical Oncology in Low- and Middle-Income Countries. Journal of Clinical Oncology, 2011, 29, 3097-3102.	0.8	24
160	The impact of lymphovascular invasion on lymph node status in patients with breast cancer. American Surgeon, 2011, 77, 874-7.	0.4	11
161	Can Sentinel Node Biopsy Be Avoided in Some Elderly Breast Cancer Patients?. Annals of Surgery, 2010, 251, 181-182.	2.1	0
162	Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer, 2010, 116, 2307-2315.	2.0	33

#	Article	IF	CITATIONS
163	Malignant Phylloides Tumor in Pregnancy. American Surgeon, 2010, 76, 302-305.	0.4	18
164	Clinical Significance of Minimal Sentinel Node Involvement and Management Options. Surgical Oncology Clinics of North America, 2010, 19, 493-505.	0.6	9
165	The Role of Sentinel Node Biopsy in Women Undergoing Prophylactic Mastectomy. Journal of Surgical Research, 2010, 164, 188-192.	0.8	25
166	The lower incidence of melanoma in women may be related to increased preventative behaviors. American Journal of Surgery, 2010, 200, 765-769.	0.9	14
167	Malignant phylloides tumor in pregnancy. American Surgeon, 2010, 76, 302-5.	0.4	13
168	Does a family history of male breast cancer influence risk perception and use of genetic testing?. American Surgeon, 2010, 76, 879-82.	0.4	3
169	Adherence to physical activity guidelines in breast cancer survivors. American Surgeon, 2010, 76, 962-5.	0.4	27
170	Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?. Surgery, 2009, 146, 561-568.	1.0	28
171	Can Sentinel Node Biopsy Be Avoided in Some Elderly Breast Cancer Patients?. Annals of Surgery, 2009, 249, 455-460.	2.1	32
172	Racial trends in mammography rates: a population-based study. Surgery, 2008, 144, 467-472.	1.0	19
173	QS132. Racial Trends in Mammography Rates: A Population-Based Study. Journal of Surgical Research, 2008, 144, 320.	0.8	0
174	The use of radiation therapy after breast-conserving surgery in hormonally treated breast cancer patients is dependent on patient age, geographic region, and surgeon specialty. American Journal of Surgery, 2008, 195, 793-798.	0.9	16
175	The recent decline in mammography rates is limited to low- to average-risk women. American Journal of Surgery, 2008, 196, 821-826.	0.9	6
176	Novel Intraoperative Molecular Test for Sentinel Lymph Node Metastases in Patients With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2008, 26, 3338-3345.	0.8	77
177	Effect of Multiple–Nodal Basin Drainage on Cutaneous Melanoma. Archives of Surgery, 2008, 143, 632.	2.3	22
178	Distant Metastasis in Elderly Patients with Breast Cancer: Prognosis with Nodal Status. , 2008, , 601-608.		0
179	Pathologic Evaluation of Cryoprobe-Assisted Lumpectomy for Breast Cancer. American Journal of Clinical Pathology, 2007, 128, 239-244.	0.4	15
180	Are 3 Sentinel Nodes Sufficient?. Archives of Surgery, 2007, 142, 456.	2.3	32

11

#	Article	IF	CITATIONS
181	A strategic approach to the evaluation of axillary lymph nodes in breast cancer patients: analysis of 168 patients at a single institution. American Journal of Surgery, 2007, 194, 524-526.	0.9	32
182	Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. American Journal of Surgery, 2007, 194, 426-432.	0.9	96
183	Factors influencing the number of sentinel lymph nodes identified in patients with breast cancer. American Journal of Surgery, 2007, 194, 860-865.	0.9	16
184	Trends in Mammography and Clinical Breast Examination: A Population-Based Study. Journal of Surgical Research, 2007, 140, 214-219.	0.8	27
185	Predicting Patients at Low Probability of Requiring Postmastectomy Radiation Therapy. Annals of Surgical Oncology, 2007, 14, 670-677.	0.7	44
186	Body Mass Index Influences Palpability but not Stage of Breast Cancer at Diagnosis. American Surgeon, 2007, 73, 555-560.	0.4	22
187	Breast carcinoma metastatic to ameloblastoma: a unique tumour-to-tumour metastasis. Histopathology, 2007, 50, 815-817.	1.6	4
188	Factors Determining Adequacy of Axillary Node Dissection in Breast Cancer Patients. Breast Journal, 2007, 13, 233-237.	0.4	24
189	Extramammary Paget?s Disease of the Axilla: An Unusual Case. Breast Journal, 2007, 13, 291-293.	0.4	12
190	Body mass index influences palpability but not stage of breast cancer at diagnosis. American Surgeon, 2007, 73, 555-60; discussion 560.	0.4	19
191	Prediction of sentinel lymph node–only disease in women with invasive breast cancerâ€â€A complete list of investigators in the University of Louisville Breast Sentinel Lymph Node Study is provided in Am J Surg 2002;184:496–8 American Journal of Surgery, 2006, 192, 882-887.	0.9	71
192	Lymphoscintigraphy and Sentinel Lymph Node Biopsy of the Internal Mammary Nodes: Is It Worth It?. Breast Diseases, 2006, 17, 131-132.	0.0	0
193	Determinants of early distant metastatic disease in elderly patients with breast cancer. American Journal of Surgery, 2006, 192, 317-321.	0.9	8
194	Prospective randomized study comparing cryo-assisted and needle-wire localization of ultrasound-visible breast tumors. American Journal of Surgery, 2006, 192, 462-470.	0.9	71
195	Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy. Annals of Surgery, 2006, 243, 257-264.	2.1	217
196	Gender-Related Differences in Outcome for Melanoma Patients. Annals of Surgery, 2006, 243, 693-700.	2.1	155
197	Predicting Extensive Nodal Disease in Women With Breast Cancer. Annals of Surgical Oncology, 2006, 13, 3-4.	0.7	3
198	Factors associated with surgical options for breast carcinoma. Cancer, 2006, 106, 1462-1466.	2.0	78

#	Article	IF	CITATIONS
199	Treatment of sentinel node-positive breast cancer. Expert Review of Anticancer Therapy, 2006, 6, 1233-1239.	1.1	6
200	Clinicopathologic Factors Associated With False-Negative Sentinel Lymph-Node Biopsy in Breast Cancer. Annals of Surgery, 2005, 241, 1005-1015.	2.1	86
201	Breast Biopsy Marker Masquerading as a Mass Lesion. Breast Journal, 2005, 11, 504-505.	0.4	3
202	Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery, 2005, 138, 56-63.	1.0	76
203	Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer, 2005, 103, 1581-1586.	2.0	103
204	Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers?. Nature Clinical Practice Oncology, 2005, 2, 448-455.	4.3	31
205	Biopsy type does not influence sentinel lymph node status. American Journal of Surgery, 2005, 190, 551-556.	0.9	14
206	Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. American Journal of Surgery, 2005, 190, 557-562.	0.9	31
207	Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. American Journal of Surgery, 2005, 190, 915-919.	0.9	23
208	Sentinel lymph node biopsy for breast cancer: from investigational procedure to standard practice. Expert Review of Anticancer Therapy, 2004, 4, 903-912.	1.1	4
209	The replication error phenotype is associated with the development of distant metastases in hormonally treated patients with breast carcinoma. Cancer, 2004, 100, 913-919.	2.0	9
210	Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer, 2004, 100, 2549-2554.	2.0	9
211	Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. American Journal of Surgery, 2004, 187, 164-169.	0.9	32
212	Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. American Journal of Surgery, 2004, 188, 399-402.	0.9	102
213	Validation of Subareolar and Periareolar Injection Techniques for Breast Sentinel Lymph Node Biopsy. Archives of Surgery, 2004, 139, 614.	2.3	80
214	Advances in the management of localized breast cancer: an overview. The Journal of the Kentucky Medical Association, 2004, 102, 202-8.	0.1	3
215	Skin-sparing and nipple-sparing mastectomy: preoperative, intraoperative, and postoperative considerations. American Surgeon, 2004, 70, 425-32.	0.4	23
216	Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: Implications for post-mastectomy radiation therapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 128-135.	0.4	29

#	Article	IF	CITATIONS
217	Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome. Annals of Surgical Oncology, 2003, 10, 628-634.	0.7	76
218	Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. American Journal of Surgery, 2003, 186, 371-377.	0.9	118
219	Outcome of Breast Cancer Patients with Chest Wall Recurrence. Cancer Journal (Sudbury, Mass), 2003, 9, 507.	1.0	0
220	Mastitis and Breast Abscess. Problems in General Surgery, 2003, 20, 27-34.	0.2	0
221	Development of an avian model for restenosis. Atherosclerosis, 1996, 119, 17-41.	0.4	13
222	Laser-induced fluorescence: III. Quantitative analysis of atherosclerotic plaque content. Lasers in Surgery and Medicine, 1995, 16, 164-178.	1.1	35
223	Colobronchial fistula due to Crohn's disease. Annals of Thoracic Surgery, 1995, 60, 446-448.	0.7	27